Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Commentary on Vorobjov et al., "Comparison of injection drug users who obtain syringes from pharmacies and syringe exchange programs in Tallinn, Estonia" | Harm Reduction Journal BioMed Central Commentary Commentary on Vorobjov et al. Comparison of injection drug users who obtain syringes from pharmacies and syringe exchange programs in Tallinn Estonia Daniel Werb1 2 and Evan Wood 1 2 Open Access Address 1British Columbia Centre for Excellence in HIV AIDS Vancouver Canada and 2School of Population and Public Health University of British Columbia Vancouver Canada Email Daniel Werb - dwerb@ Evan Wood - uhri-ew@ Corresponding author Published 27 November 2009 Received 22 July 2009 Accepted 27 November 2009 Harm Reduction Journal 2009 6 33 doi l 477-7517-6-33 This article is available from http content 6 1 33 2009 Werb and Wood licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Recent data suggest that globally between 5 and 10 of all new HIV cases are the result of unsafe injecting practices and experts agree that reducing these practices is key to tackling the spread of HIV. And yet despite the overwhelming evidence that providing sterile syringes to injection drug users IDU through syringe exchange programs SEPs or other means is an effective way of reducing HIV transmission among high-risk subpopulations IDU in most settings still do not have access to sterile injecting equipment or if they do access remains too restricted to effectively reduce the risk of HIV transmission. Vorobjov and colleagues have presented in this journal an interesting and timely study from Estonia comparing individuals who obtain syringes from SEPs and those who obtain syringes from pharmacies. As the authors point out Estonia faces an unacceptably high HIV incidence rate of 50 new HIV cases per 100 000 this rate driven primarily by .
